Vistagen Therapeutics Earnings Report: Q3 Overview
Benzinga Insights 9 months ago
Earnings
Vistagen Therapeutics (NASDAQ:VTGN) just disclosed its Q3 earnings on Thursday, February 12, 2026 at 04:20 PM.
Here's a brief overview of the earnings report.
Earnings
Vistagen Therapeutics missed estimated earnings by -15.38%, reporting an EPS of $-0.45 versus an estimate of $-0.39.
Revenue was up $69 thousand from the same period last year.
Past Earnings Performance
The company missed on EPS by $0.07 in the previous quarter, leading to a 0.0% increase share price change the next day.
Here's a look at Vistagen Therapeutics's past performance:
| Quarter | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|
| EPS Estimate | -0.47 | -0.45 | -0.49 | -0.52 |
| EPS Actual | -0.54 | -0.47 | -0.44 | -0.46 |
| Revenue Estimate | 339K | 389K | 209K | 179K |
| Revenue Actual | 258K | 244K | -15K | 234K |
To track all earnings releases for Vistagen Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.